AbbVie Sees Heavy Put Activity as Traders Target $265 Strike Ahead of November Expiration

By TrendSpider Editor

The forward setup for ABBV warrants close attention heading into the November expiration window. The stock has made a remarkable recovery over the past year, climbing from a 52-week low of $191.00 to its current level of $284.98, a gain that could make it an attractive candidate for profit-taking. W

AbbVie Sees Heavy Put Activity as Traders Target $265 Strike Ahead of November Expiration

Key Drivers of the ABBV Stock Move

• Main Catalyst: All six unusual options contracts flagged today are puts, with five of the six clustering at the $265 strike expiring November 20, 2026. The dominant block involved 2,543 contracts at that strike, carrying $851,905 in premium and an open interest ratio of 12,715%, indicating this position dwarfs existing open interest at that level by a wide margin. A separate $277.5 put expiring the same date saw 200 contracts change hands at an open interest ratio of 328% and $126,000 in premium.
• Bull Case: ABBV shares are up 0.09% on the session and remain close to their 52-week high of $291.33, reflecting underlying strength in the stock. The put strikes at $265 sit more than 7% below the current price of $284.98, meaning these contracts are out of the money and could simply represent hedging activity by long holders protecting gains accumulated over a strong run from the 52-week low of $191.00.
• Bear Case: The sheer concentration of $851,905 in premium on a single $265 put block, combined with an open interest ratio of 12,715%, is difficult to explain away as routine hedging. Five separate $265-strike put contracts hit the tape today, pointing to deliberate, repeated positioning at that level ahead of the November 20 expiration. Traders willing to pay this much premium for downside protection this far out of the money typically have conviction behind the trade.

The forward setup for ABBV warrants close attention heading into the November expiration window. The stock has made a remarkable recovery over the past year, climbing from a 52-week low of $191.00 to its current level of $284.98, a gain that could make it an attractive candidate for profit-taking. Whether today's put flow represents directional bets or large-scale portfolio hedging, the volume and premium concentration at the $265 strike establish a clear level that the options market is watching. Traders should monitor whether additional put flow continues to build at this strike in coming sessions, as sustained accumulation would strengthen the bearish thesis embedded in today's activity.

ABBV Unusual Options Activity

All six flagged contracts today are puts, with activity concentrated almost entirely at the $265 strike expiring November 20, 2026. Details for each contract are as follows:

• PUT | Strike: $277.50 | Expiry: November 20, 2026 | Volume: 200 | OI%: 328%
• PUT | Strike: $265.00 | Expiry: November 20, 2026 | Volume: 472 | OI%: 2,360%
• PUT | Strike: $265.00 | Expiry: November 20, 2026 | Volume: 257 | OI%: 1,285%
• PUT | Strike: $265.00 | Expiry: November 20, 2026 | Volume: 213 | OI%: 1,065%
• PUT | Strike: $265.00 | Expiry: November 20, 2026 | Volume: 176 | OI%: 880%
• PUT | Strike: $265.00 | Expiry: November 20, 2026 | Volume: 2,543 | OI%: 12,715%

Every contract flagged today is out of the money relative to the current share price of $284.98. The total premium across all six contracts is $1,323,470, with the single largest block accounting for $851,905 of that total. The complete absence of call activity among today's unusual contracts reinforces the one-sided, bearish nature of today's options flow.

ABBV Seasonality

Late October through November has historically been an active period for large-cap pharmaceutical names, as year-end portfolio rebalancing and upcoming earnings cycles often drive elevated options activity. The November 20, 2026 expiration date falls squarely within this seasonally sensitive window, which may partly explain why traders are choosing this expiry to express directional views or lock in downside protection.

ABBV Relative Performance

ABBV's current price of $284.98 represents a gain of roughly 49% from its 52-week low of $191.00 and places it within approximately 2.2% of its 52-week high of $291.33. This positioning near the top of its annual range suggests ABBV has significantly outperformed broad market benchmarks and many of its large-cap pharmaceutical peers over the past year, which may itself be a factor motivating the defensive put positioning observed in today's session.